Antimalarial iron chelator, FBS0701, shows asexual and gametocyte Plasmodium falciparum activity and single oral dose cure in a murine malaria model

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Ferrer, Patricia ^a   Tripathi, Abhai K ^a   Clark, Martha A ^b   Hand, Carla Cerami ^c   Rienhoff, Hugh Young ^d   Sullivan, David J ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c IL   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3'' (HO) DESAZADESFERRITHIOCIN POLYETHER; ANTIMALARIAL AGENT; ARTEMISININ; CHLOROQUINE; DEFERIPRONE; DEFEROXAMINE; FBS 0701; IRON CHELATING AGENT; QUININE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIMALARIAL ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG EXPOSURE; DRUG POTENTIATION; ERYTHROCYTE; GAMETOCYTE; IC 50; IRON CHELATION; MALE; MONOTHERAPY; MOUSE; NONHUMAN; PLASMODIUM BERGHEI INFECTION; PLASMODIUM FALCIPARUM; PLASMODIUM YOELII INFECTION; SINGLE DRUG DOSE; SURVIVAL TIME;

MURINAE; MUS; PLASMODIUM FALCIPARUM;

EID: 84861314596     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0037171     Document Type: Article

References (27)

1. Sullivan DJ Jr, Gluzman IY, Russell DG, Goldberg DE, (1996) On the molecular mechanism of chloroquine's antimalarial action. Proc Natl Acad Sci U S A 93: 11865-11870.
2. O'Neill PM, Posner GH, (2004) A medicinal chemistry perspective on artemisinin and related endoperoxides. J Med Chem 47: 2945-2964.
3. Mabeza GF, Loyevsky M, Gordeuk VR, Weiss G, (1999) Iron chelation therapy for malaria: a review. Pharmacol Ther 81: 53-75.
4. Gordeuk VR, Thuma PE, Brittenham GM, Zulu S, Simwanza G, et al. (1992) Iron chelation with desferrioxamine B in adults with asymptomatic Plasmodium falciparum parasitemia. Blood 79: 308-312.
5. Gordeuk V, Thuma P, Brittenham G, McLaren C, Parry D, et al. (1992) Effect of iron chelation therapy on recovery from deep coma in children with cerebral malaria. N Engl J Med 327: 1473-1477.
6. Thuma PE, Olivieri NF, Mabeza GF, Biemba G, Parry D, et al. (1998) Assessment of the effect of the oral iron chelator deferiprone on asymptomatic Plasmodium falciparum parasitemia in humans. Am J Trop Med Hyg 58: 358-364.
7. Portugal S, Carret C, Recker M, Armitage AE, Goncalves LA, et al. (2011) Host-mediated regulation of superinfection in malaria. Nat Med 17: 732-737.
8. Goma J, Renia L, Miltgen F, Mazier D, (1996) Iron overload increases hepatic development of Plasmodium yoelii in mice. Parasitology 112 (Pt 2): 165-168.
9. Eckstein-Ludwig U, Webb RJ, Van Goethem ID, East JM, Lee AG, et al. (2003) Artemisinins target the SERCA of Plasmodium falciparum. Nature 424: 957-961.
10. Wang J, Huang L, Li J, Fan Q, Long Y, et al. (2010) Artemisinin directly targets malarial mitochondria through its specific mitochondrial activation. PLoS One 5: e9582.
11. Bergeron RJ, Wiegand J, Bharti N, McManis JS, Singh S, (2011) Desferrithiocin analogue iron chelators: iron clearing efficiency, tissue distribution, and renal toxicity. Biometals 24: 239-258.
12. Bergeron RJ, Wiegand J, McManis JS, Bharti N, Singh S, (2008) Design, synthesis, and testing of non-nephrotoxic desazadesferrithiocin polyether analogues. J Med Chem 51: 3913-3923.
13. Rienhoff HY Jr, Viprakasit V, Tay L, Harmatz P, Vichinsky E, et al. (2011) A phase 1 dose-escalation study: safety, tolerability, and pharmacokinetics of FBS0701, a novel oral iron chelator for the treatment of transfusional iron overload. Haematologica 96: 521-525.
14. Bennett TN, Paguio M, Gligorijevic B, Seudieu C, Kosar AD, et al. (2004) Novel, rapid, and inexpensive cell-based quantification of antimalarial drug efficacy. Antimicrob Agents Chemother 48: 1807-1810.
15. Elion GB, Singer S, Hitchings GH, (1954) Antagonists of nucleic acid derivatives. VIII. Synergism in combinations of biochemically related antimetabolites. J Biol Chem 208: 477-488.
16. Bell A, (2005) Antimalarial drug synergism and antagonism: mechanistic and clinical significance. FEMS Microbiol Lett 253: 171-184.
17. Buchholz K, Burke TA, Williamson KC, Wiegand RC, Wirth DF, et al. (2011) A high-throughput screen targeting malaria transmission stages opens new avenues for drug development. J Infect Dis 203: 1445-1453.
18. Darbari D, Loyevsky M, Gordeuk V, Kark JA, Castro O, et al. (2003) Fluorescence measurements of the labile iron pool of sickle erythrocytes. Blood 102: 357-364.
19. Loyevsky M, John C, Dickens B, Hu V, Miller JH, et al. (1999) Chelation of iron within the erythrocytic Plasmodium falciparum parasite by iron chelators. Mol Biochem Parasitol 101: 43-59.
20. Prus E, Fibach E, (2008) The labile iron pool in human erythroid cells. Br J Haematol 142: 301-307.
21. Meshnick SR, Yang YZ, Lima V, Kuypers F, Kamchonwongpaisan S, et al. (1993) Iron-dependent free radical generation from the antimalarial agent artemisinin (qinghaosu). Antimicrob Agents Chemother 37: 1108-1114.
22. Petritus PM, Burns JM Jr, (2008) Suppression of lethal Plasmodium yoelii malaria following protective immunization requires antibody-, IL-4-, and IFN-gamma-dependent responses induced by vaccination and/or challenge infection. J Immunol 180: 444-453.
23. Prus E, Fibach E, (2008) Flow cytometry measurement of the labile iron pool in human hematopoietic cells. Cytometry A 73: 22-27.
24. Shvartsman M, Fibach E, Cabantchik ZI, (2010) Transferrin-iron routing to the cytosol and mitochondria as studied by live and real-time fluorescence. Biochem J 429: 185-193.
25. Horky J, Vacha J, Znojil V, (1978) Comparison of life span of erythrocytes in some inbred strains of mouse using 14C-labelled glycine. Physiol Bohemoslov 27: 209-217.
26. Walker WS, Singer JA, Morrison M, Jackson CW, (1984) Preferential phagocytosis of in vivo aged murine red blood cells by a macrophage-like cell line. Br J Haematol 58: 259-266.
27. Freireich EJ, Gehan EA, Rall DP, Schmidt LH, Skipper HE, (1966) Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep 50: 219-244.